BBS Faculty Member - Neena Haider

Neena Haider

Department of Ophthalmology,

The Schepens Eye Research Institute
20 Staniford Street
Boston, MA 02114
Tel: 617-912-0270
Visit my lab page here.

The long-term goal of my laboratory is to identify and evaluate genetic determinants underlying inherited retinal diseases and develop appropriate therapeutic interventions to prevent and treat the blindness associated with these disorders. Our research includes genetic models for Mendelian retinal diseases such as retinitis pigmentosa (RP) as well as complex diseases such as age related macular dystrophy (AMD) and diabetic retinopathy. We utilize current molecular genetics and genomics approaches including whole exome sequencing, in vivo, ex vivo, and in vitro assays to study retinal degeneration, photoreceptor regeneration, neovascularization, and potential therapeutics that ameliorate or attenuate the disease phenotypes in each of these models. I have developed or acquired approximately 30 unique mouse models that include spontaneous mutants, conditional knockouts using cre-lox technology to target rod and cone photoreceptor cells as well as retinal progenitor cells, models that express GFP in their rods or cones, and most recently we are developing complex models for AMD with multiple gene knockouts using CRISPR technology.

Current research projects include:
1. develop and test novel gene therapies for retinal disease
2. study the role of nuclear hormone receptors in photoreceptor development and function
3. identify the genetic causes of AMD
4. study the role of nuclear hormone receptors in ocular regeneration and cell therapy
5. identify novel causes and therapies for retinal neovascular disease
6. identify genetic modifiers and novel mutations in patients with retinal disease
7. the role of nuclear hormone receptors in cell cycle regulation and cancer

Last Update: 9/16/2015


For a complete listing of publications click here.



Cruz, NM, Yuan, Y, Leehy, B, Baid, R, Kompella, U, DeAngelis, MM, Escher, P, Haider, NB. Modifier Genes as therapeutics: the nuclear hormone receptor Rev Erb Alpha rescues Nr2e3 associated retinal disease. PLOS One 2014:9(1)e87942.

Owen, LA, Morrison, MA, Ahn, J, Woo, SJ, Sato H, Robinson R, Morgan DJ, Zacharaki F, Simeonova M, Uehara H, Chakravarthy U, Hogg RE, Ambati BK, Kotoula M, Baehr W,
Haider NB, Silvestri G, Miller JW, Tsironi EE, Farrer LA, Kim IK, Park KH, DeAngelis MM FLT1 Genetic Variation Predisposes to Neovascular AMD in Ethnically Diverse Populations and Alters Systemic FLT1 Expression. IOVS, 2014, IOVS, 2014:55(6)3543-3554.

Jelcick, AS, Yuan Y, Leehy, BD, Cox, L, Silveira, AC, Schenk, S, Qui, F, Sachs, AJ, Morrison, MA, DeAngelis, MM, Nystuen, AM,
Haider, NB* (2011) Genetic Variations Strongly Influence Phenotypic Outcome in the Mouse Retina, PLoS One 6(7): e21858. PMCID:

Mollema, N, Yuan, Y, Escher, P, L, Silveira, AC, Morrison, MA, DeAngelis, MM, Nystuen, AM,
Haider, NB (2011) Nuclear receptor Rev-erbalpha (Nr1d1) Functions in Concert with Nr2e3 to Regulate Transcriptional Networks in the Retina. PLoS One 6(3): e17494. PMCID:

© 2016 President and Fellows
of Harvard College